Skip to main content
Erschienen in: Supportive Care in Cancer 3/2008

01.03.2008 | Short Communication

Radiation-Induced trismus in head and neck cancer patients

verfasst von: M. Louise Kent, Michael T. Brennan, Jenene L. Noll, Philip C. Fox, Stuart H. Burri, Jane C. Hunter, Peter B. Lockhart

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the incidence of trismus in patients who had previously received curative doses of radiation therapy (RT) for head and neck cancer. In addition, we assessed if trismus was associated with quality of life deficits and radiation toxicity.

Methods and materials

Between February, 2005 and December, 2006, 40 patients with histologically confirmed head and neck cancer who had received curative doses of RT to the area(s) of the masticatory muscles and/or the ligaments of the temporomandibular joint (TMJ) were enrolled in this study. Differences in trismus incidence were compared between cancer treatment modalities [i.e., RT vs RT/chemotherapy (CT) and conventional RT vs intensity modulated RT]. Quality of life (QOL) was measured by using four questions from the EORTC QLQ-C30 that address pain and difficulty opening the jaw. Scores regarding impaired eating as a result of decreased range of motion of the mouth were derived from the Modified Common Toxicity Criteria (CTCAE Version 3.0).

Results

Trismus was identified in 45% of subjects who had received curative doses of RT. No differences were noted in the incidence of trismus between RT and RT/CT or between conventional RT and intensity modulated RT (IMRT). Those with trismus demonstrated more QOL deficits than the non-trismus group.

Conclusions

Curative doses of RT for head and neck cancer result in trismus in a high percentage of patients, independent of other treatment modalities. Trismus has a negative impact on quality of life in this population.
Literatur
1.
Zurück zum Zitat Cox JD, Ang KK (2003) Radiation oncology: rationale, technique, results, 8 edn. Mosby, Philadelphia Cox JD, Ang KK (2003) Radiation oncology: rationale, technique, results, 8 edn. Mosby, Philadelphia
2.
Zurück zum Zitat Perez CA, Brady LW (2004) Principles and practice of radiation oncology, 4 edn. Lippincott Williams & Wilkins, Philadelphia Perez CA, Brady LW (2004) Principles and practice of radiation oncology, 4 edn. Lippincott Williams & Wilkins, Philadelphia
3.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMedCrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMedCrossRef
4.
Zurück zum Zitat Bourhis J, Le MA, Baujat B, Audry H, Pignon JP, Meta-Analysis of Chemotherapy in Head NCCG, Meta-Analysis of Radiotherapy in Carcinoma of Head NCG, Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma Collaborative Group (2007) Individual patients’ data meta-analyses in head and neck cancer. Curr Opin Oncol 19(3):188–194PubMedCrossRef Bourhis J, Le MA, Baujat B, Audry H, Pignon JP, Meta-Analysis of Chemotherapy in Head NCCG, Meta-Analysis of Radiotherapy in Carcinoma of Head NCG, Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma Collaborative Group (2007) Individual patients’ data meta-analyses in head and neck cancer. Curr Opin Oncol 19(3):188–194PubMedCrossRef
5.
Zurück zum Zitat Corry J, Rischin D, Smith JG, D’Costa IA, Huges PG, Sexton MA, Sizeland A, Lyons B, Peters LJ (2000) Radiation with concurrent late chemotherapy intensification (‘chemoboost’) for locally advanced head and neck cancer. Radiotherapy & Oncology 54(2):123–127CrossRef Corry J, Rischin D, Smith JG, D’Costa IA, Huges PG, Sexton MA, Sizeland A, Lyons B, Peters LJ (2000) Radiation with concurrent late chemotherapy intensification (‘chemoboost’) for locally advanced head and neck cancer. Radiotherapy & Oncology 54(2):123–127CrossRef
6.
Zurück zum Zitat Goldstein M, Maxymiw WG, Cummings BJ, Wood RE (1999) The effects of antitumor irradiation on mandibular opening and mobility: a prospective study of 58 patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88(3):365–373PubMedCrossRef Goldstein M, Maxymiw WG, Cummings BJ, Wood RE (1999) The effects of antitumor irradiation on mandibular opening and mobility: a prospective study of 58 patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88(3):365–373PubMedCrossRef
7.
Zurück zum Zitat Ichimura K, Tanaka T (1993) Trismus in patients with malignant tumours in the head and neck. Journal of Laryngology & Otology 107(11):1017–1020 Ichimura K, Tanaka T (1993) Trismus in patients with malignant tumours in the head and neck. Journal of Laryngology & Otology 107(11):1017–1020
8.
Zurück zum Zitat Janinis J, Papadakou M, Panagos G, Panousaki A, Georgoulias V, Hatzidaki D, Lefantzis D, Dokianakis G (2001) Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 24(3):227–231PubMedCrossRef Janinis J, Papadakou M, Panagos G, Panousaki A, Georgoulias V, Hatzidaki D, Lefantzis D, Dokianakis G (2001) Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 24(3):227–231PubMedCrossRef
9.
Zurück zum Zitat Krengli M, Masini L, Gambaro G, Turri L, Loi G, Aluffi P, Pia F (2001) Concurrent chemotherapy with carboplatin + 5-fluorouracil and radiotherapy in advanced squamous cell head and neck carcinoma: a retrospective single institution’s study. Tumori 87(5):312–316PubMed Krengli M, Masini L, Gambaro G, Turri L, Loi G, Aluffi P, Pia F (2001) Concurrent chemotherapy with carboplatin + 5-fluorouracil and radiotherapy in advanced squamous cell head and neck carcinoma: a retrospective single institution’s study. Tumori 87(5):312–316PubMed
10.
Zurück zum Zitat Maloney GE, Mehta N, Forgione AG, Zawawi KH, Al-Badawi EA, Driscoll SE (2002) Effect of a passive jaw motion device on pain and range of motion in TMD patients not responding to flat plane intraoral appliances. J Craniomandibular Pract 20(1):55–66 Maloney GE, Mehta N, Forgione AG, Zawawi KH, Al-Badawi EA, Driscoll SE (2002) Effect of a passive jaw motion device on pain and range of motion in TMD patients not responding to flat plane intraoral appliances. J Craniomandibular Pract 20(1):55–66
11.
Zurück zum Zitat National Cancer Institute (2003) Common terminology criteria for adverse events (CTCAE), Version 3.0 edn. Cancer Therapy Evaluation Program, Bethesda, MD National Cancer Institute (2003) Common terminology criteria for adverse events (CTCAE), Version 3.0 edn. Cancer Therapy Evaluation Program, Bethesda, MD
12.
Zurück zum Zitat Nguyen TD, Panis X, Froissart D, Legros M, Coninx P, Loirette M (1988) Analysis of late complications after rapid hyperfractionated radiotherapy in advanced head and neck cancers. Int J Radiat Oncol Biol Phys 14(1):23–25PubMed Nguyen TD, Panis X, Froissart D, Legros M, Coninx P, Loirette M (1988) Analysis of late complications after rapid hyperfractionated radiotherapy in advanced head and neck cancers. Int J Radiat Oncol Biol Phys 14(1):23–25PubMed
13.
Zurück zum Zitat Okunieff P, Augustine E, Hicks JE, Cornelison TL, Altemus RM, Naydich BG, Ding I, Huser AK, Abraham EH, Smith JJ et al (2004) Pentoxifylline in the treatment of radiation-induced fibrosis. J Clin Oncol 22(11):2207–2213PubMedCrossRef Okunieff P, Augustine E, Hicks JE, Cornelison TL, Altemus RM, Naydich BG, Ding I, Huser AK, Abraham EH, Smith JJ et al (2004) Pentoxifylline in the treatment of radiation-induced fibrosis. J Clin Oncol 22(11):2207–2213PubMedCrossRef
14.
Zurück zum Zitat Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. CA Cancer J Clin 49(1):33–64PubMed Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. CA Cancer J Clin 49(1):33–64PubMed
15.
Zurück zum Zitat Regine WF, Valentino J, John W, Storey G, Sloan D, Kenady D, Patel P, Pulmano C, Arnold SM, Mohiuddin M (2000) High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: report of a phase II study. Head Neck 22:543–549PubMedCrossRef Regine WF, Valentino J, John W, Storey G, Sloan D, Kenady D, Patel P, Pulmano C, Arnold SM, Mohiuddin M (2000) High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: report of a phase II study. Head Neck 22:543–549PubMedCrossRef
16.
Zurück zum Zitat Robbins KT, Kumar P, Wong FS, Hartsell WF, Flick P, Palmer R, Weir AB III, Neill HB, Murry T, Ferguson R et al (2000) Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck 22(7):687–693PubMedCrossRef Robbins KT, Kumar P, Wong FS, Hartsell WF, Flick P, Palmer R, Weir AB III, Neill HB, Murry T, Ferguson R et al (2000) Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck 22(7):687–693PubMedCrossRef
17.
Zurück zum Zitat Samant S, Kumar P, Wan J, Hanchett C, Vieira F, Murry T, Wong FS, Robbins KT (1999) Concomitant radiation therapy and targeted cisplatin chemotherapy for the treatment of advanced pyriform sinus carcinoma: disease control and preservation of organ function. Head Neck 21(7):595–601PubMedCrossRef Samant S, Kumar P, Wan J, Hanchett C, Vieira F, Murry T, Wong FS, Robbins KT (1999) Concomitant radiation therapy and targeted cisplatin chemotherapy for the treatment of advanced pyriform sinus carcinoma: disease control and preservation of organ function. Head Neck 21(7):595–601PubMedCrossRef
18.
Zurück zum Zitat Sessions RB, Harrison LB, Forastiere AA (1997) Tumors of the larynx and hypopharynx. In: DeVita VT Jr., Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 5th edn. Lippincott-Raven Publishers, Philadelphia, pp 802–29 Sessions RB, Harrison LB, Forastiere AA (1997) Tumors of the larynx and hypopharynx. In: DeVita VT Jr., Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 5th edn. Lippincott-Raven Publishers, Philadelphia, pp 802–29
19.
Zurück zum Zitat Teh BS, Monga U, Thornby J, Gressot L, Parke RB, Donovan DT (2000) Concurrent chemotherapy and “concomitant boost” radiotherapy for unresectable head and neck cancer. Am J Otolaryngol 21(5):306–311PubMedCrossRef Teh BS, Monga U, Thornby J, Gressot L, Parke RB, Donovan DT (2000) Concurrent chemotherapy and “concomitant boost” radiotherapy for unresectable head and neck cancer. Am J Otolaryngol 21(5):306–311PubMedCrossRef
20.
Zurück zum Zitat Toljanic JA, Heshmati RH, Bedard JF (2002) Dental follow-up compliance in a population of irradiated head and neck cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93(1):35–38PubMedCrossRef Toljanic JA, Heshmati RH, Bedard JF (2002) Dental follow-up compliance in a population of irradiated head and neck cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93(1):35–38PubMedCrossRef
21.
Zurück zum Zitat Vissink A, Jansma J, Spijkervet FK, Burlage FR, Coppes RP (2003) Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14(3):199–212PubMedCrossRef Vissink A, Jansma J, Spijkervet FK, Burlage FR, Coppes RP (2003) Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14(3):199–212PubMedCrossRef
22.
Zurück zum Zitat Wang CJ, Huang EY, Hsu HC, Chen HC, Fang FM, Hsiung CY (2005) The degree and time-course assessment of radiation-induced trismus occurring after radiotherapy for nasopharyngeal cancer. Laryngoscope 115(8):1458–1460PubMedCrossRef Wang CJ, Huang EY, Hsu HC, Chen HC, Fang FM, Hsiung CY (2005) The degree and time-course assessment of radiation-induced trismus occurring after radiotherapy for nasopharyngeal cancer. Laryngoscope 115(8):1458–1460PubMedCrossRef
23.
Zurück zum Zitat Whitmyer CC, Waskowski JC, Iffland HA (1997) Radiotherapy and oral sequelae: preventive and management protocols. J Dent Hyg 71(1):23–29PubMed Whitmyer CC, Waskowski JC, Iffland HA (1997) Radiotherapy and oral sequelae: preventive and management protocols. J Dent Hyg 71(1):23–29PubMed
Metadaten
Titel
Radiation-Induced trismus in head and neck cancer patients
verfasst von
M. Louise Kent
Michael T. Brennan
Jenene L. Noll
Philip C. Fox
Stuart H. Burri
Jane C. Hunter
Peter B. Lockhart
Publikationsdatum
01.03.2008
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 3/2008
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0345-5

Weitere Artikel der Ausgabe 3/2008

Supportive Care in Cancer 3/2008 Zur Ausgabe

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.